Daewoong Pharmaceutical has officially launched the world’s first ring-type continuous blood pressure monitor, “CART BP Pro,” following its recent inclusion in the national health insurance reimbursement scheme.
The company announced on August 27 that the device, developed by SkyLabs, has been approved by the Health Insurance Review and Assessment Service (HIRA) and is now available in the market.
The CART BP Pro addresses the discomfort associated with traditional cuff-based blood pressure monitors, which require upper-arm cuffs and can disrupt daily activities and sleep.
Instead, this ring-type device, worn on the finger, continuously monitors blood pressure for 24 hours using advanced biosensors and AI technology to analyze blood flow and provide accurate readings.
The data is automatically sent to healthcare providers, allowing for precise monitoring of blood pressure fluctuations throughout the day.
The inclusion of CART BP in the insurance reimbursement list is expected to significantly increase accessibility for Korea’s 12 million hypertension patients, reducing their financial burden.
The estimated out-of-pocket cost for patients is expected to be between 5,000 and 9,000 KRW per day. Daewoong Pharmaceutical plans to first distribute the hospital-use model “CART BP Pro” and expand to a consumer version that doesn’t require a prescription by the first half of next year.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, emphasized that the inclusion of CART BP in the insurance reimbursement list marks a significant step forward in the use of digital wearable devices for the prevention and treatment of hypertension.
He added that the company would leverage its marketing experience with other digital healthcare products, such as the Mobicare ECG monitor and the Athea AI ECG analysis software, to drive the market penetration of it.
Editor 메디마스터
Provided by: DAEWOONG
UNIST·와이즈만 연구진, 단백질 효소 기계적 작동 원리 규명 우리 몸속 생화학 반응을 조절하는 '단백질 효소'…
식약처, 메틸페니데이트 처방 감시 체계 확대 — ADHD 환자 치료제 사용, 관리 강화된다 식품의약품안전처(처장 오유경)는…